专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU3071392A DNA ENCODING A GLYCINE TRANSPORTER AND USES THEREOF 未知
公开(公告)号：AU3071392A
公开(公告)日：1993-06-15
申请号：AU3071392
申请日：1992-11-12
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION
发明人： KELLI SMITH , LAURENCE A BORDEN , THERESA BRANCHEK , PAUL R HARTIG , RICHARD L WEINSHANK
IPC分类号： C12N15/00 , A61K38/00 , C07K14/47
摘要： PCT No. PCT/US92/09662 Sec. 371 Date Nov. 10, 1994 Sec. 102(e) Date Nov. 10, 1994 PCT Filed Nov. 12, 1992 PCT Pub. No. WO93/10228 PCT Pub. Date May 27, 1993This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammalian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human glycine transporter, pharmaceutical compounds related to mammalian glycine transporter, pharmaceutical compounds related to human glycine transporter and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human glycine transporter. This invention also provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian glycine transporter. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human glycine transporter.

2. 发明申请

US20040214237A1 DNA encoding SNORF138 and uses thereof 审中-公开
标题翻译：编码SNORF138的DNA及其用途
公开(公告)号：US20040214237A1
公开(公告)日：2004-10-28
申请号：US10679185
申请日：2003-10-03
申请人： Synaptic Pharmaceutical Corporation
发明人： Roman Artymyshyn , Liliana Delgado , Pierre J. Vaysse , Hong Zhang , Weinong Guo
IPC分类号： G01N033/53 , G01N033/567
CPC分类号： G01N33/74 , G01N2333/726 , G01N2500/00
摘要： This invention provides methods of treating an abnormality that is linked to the activity of the mammalian SNORF138 receptor, as well as methods of determining binding of compounds to the mammalian SNORF138 receptor, methods of identifying agonists and antagonists of the SNORF138 receptor, and agonists and antagonists so identified.
摘要翻译：本发明提供了治疗与哺乳动物SNORF138受体的活性相关的异常的方法，以及确定化合物与哺乳动物SNORF138受体的结合的方法，鉴定SNORF138受体的激动剂和拮抗剂的方法，以及激动剂和拮抗剂如此确定。

3. 发明申请

US20030143729A1 DNA encoding taurine and GABA transporters and uses thereof 审中-公开
标题翻译：编码牛磺酸和GABA转运蛋白的DNA及其用途
公开(公告)号：US20030143729A1
公开(公告)日：2003-07-31
申请号：US09845908
申请日：2001-04-30
申请人： Synaptic Pharmaceutical Corporation
发明人： Kelli E. Smith , Laurence A. Borden , Richard L. Weinshank , Paul R. Hartig
IPC分类号： C12P021/02 , C12N005/06 , C07H021/04 , C12N015/00
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00
摘要： This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABA or taurine transporters, or normal or mutant human GABA or taurine transporters are provided. Further provided are methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian GABA or taurine transporters, or human GABA or taurine transporters.
摘要翻译：本发明提供编码两种哺乳动物GABA转运蛋白的分离的核酸分子，哺乳动物牛磺酸转运蛋白和两种人GABA转运蛋白; 分离这些核酸分子的方法和包含此类核酸分子的载体以及包含这些载体的哺乳动物细胞。用于检测编码哺乳动物或人GABA转运蛋白或哺乳动物或人牛磺酸转运蛋白的核酸分子的核酸探针; 与编码哺乳动物GABA或牛磺酸转运蛋白或人GABA或牛磺酸转运蛋白的核酸分子的任何序列互补的反义寡核苷酸; 并提供对哺乳动物GABA或牛磺酸转运蛋白或人GABA或牛磺酸转运蛋白的抗体。提供了与哺乳动物GABA或牛磺酸转运蛋白和人GABA或牛磺酸转运蛋白相关的药物化合物。提供了表达编码正常或突变的哺乳动物GABA或牛磺酸转运蛋白的DNA的非人类转基因动物，或正常或突变的人GABA或牛磺酸转运蛋白。还提供了用于确定底物结合，检测表达，药物筛选和用于减轻与哺乳动物GABA或牛磺酸转运蛋白或人GABA或牛磺酸转运蛋白相关的异常的治疗的方法。

4. 发明申请

US20030049794A1 DNA encoding a human dopamine D1 receptor and uses thereof 失效
公开(公告)号：US20030049794A1
公开(公告)日：2003-03-13
申请号：US10277078
申请日：2002-10-21
申请人： Synaptic Pharmaceutical Corporation
发明人： Richard L. Weinshank , Paul R. Hartig
IPC分类号： C07K014/705 , C07H021/04 , C12P021/02 , C12N001/21 , C12N005/06 , C12N001/18 , C12N015/74
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2267/03 , A01K2267/0318 , A01K2267/0337 , A01K2267/0356 , A61K38/00 , C07K14/70571 , C12Q1/6883 , G01N33/566 , G01N33/9413 , G01N2333/70571 , G01N2500/00
摘要： This invention provides isolated nucleic acid molecules encoding a human dopamine D1 receptor, isolated proteins which are human dopamine D1 receptor, vectors comprising isolated nucleic acid molecules encoding a human dopamine D1 receptor, mammalian cells comprising such vectors, antibodies directed to a human dopamine D1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human dopamine D1 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human dopamine D1 receptor, pharmaceutical compounds related to human dopamine D1 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant human dopamine D1 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving a human dopamine D1 receptor.

5. 发明专利

TW200404779A 二芳基酮GALR3拮抗劑之方法和多晶型物 PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS 审中-公开
简体标题：二芳基酮GALR3拮抗剂之方法和多晶型物 PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS
公开(公告)号：TW200404779A
公开(公告)日：2004-04-01
申请号：TW092121466
申请日：2003-08-06
申请人：辛納波堤克製藥股份有限公司 SYNAPTIC PHARMACEUTICAL CORPORATION
发明人：約翰麥爾斯威徹爾 WETZEL, JOHN MYLES , 佛瑞伊約賓恩 JUBIAN, VREJ , 大衛T 約內伊堤斯 JONAITIS, DAVID T. , 克利斯堤昂M 雪爾茲 SCHERTZ, CHRISTINE M. , 麥可歐內爾 O'NEILL, MICHAEL
IPC分类号： C07D
CPC分类号： C07D209/40
摘要：本發明係關於化合物I〔1–苯基–3–〔〔3–(三氟甲基)苯基〕亞胺基〕–1H––2–酮〕的晶型及非晶型物，彼等的製備方法，含彼等之組成物及此等組成物之治療用途。本發明進一步關於製備化合物I之方法。
简体摘要：本发明系关于化合物I〔1–苯基–3–〔〔3–(三氟甲基)苯基〕亚胺基〕–1H––2–酮〕的晶型及非晶型物，彼等的制备方法，含彼等之组成物及此等组成物之治疗用途。本发明进一步关于制备化合物I之方法。

6. 发明专利

TW200410937A 治療抑鬱及/或焦慮症之3-亞胺基-2-酮化物 3-IMINO-2-INDOLONES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY 审中-公开
简体标题：治疗抑郁及/或焦虑症之3-亚胺基-2-酮化物 3-IMINO-2-INDOLONES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY
公开(公告)号：TW200410937A
公开(公告)日：2004-07-01
申请号：TW092121747
申请日：2003-08-07
申请人：辛那堤克製藥公司 SYNAPTIC PHARMACEUTICAL CORPORATION
发明人：麥可康凱爾 MICHAEL KONKEL , 約翰M 維塞爾 JOHN M. WETZEL , 傑米泰利斯曼 JAMIE TALISMAN
IPC分类号： C07D , A61K
CPC分类号： C07D401/04 , C07D209/40
摘要：本發明係有關對Ga1R3受體具有選擇拮抗性之酮衍生物。本發明提供一種醫藥組合物，其包含治療有效量之本發明化合物及醫藥可接受性載劑。本發明亦提供一種藉由結合治療有效量之本發明化合物及醫藥可接受性載劑所製得之醫藥組合物。本發明另提供一種製造醫藥組合物之方法，其包括結合治療有效量之本發明化合物及醫藥可接受性載劑。本發明亦提供一種治療患有抑鬱及／或焦慮症之個體之方法，其包括對該個體投予有效治療該個體抑鬱及／或焦慮症之量之本發明化合物。本發明亦提供一種於個體中治療抑鬱及／或焦慮症之方法，其包括對該個體投予包含醫藥可接受性載劑及治療有效量之Ga1R3受體拮抗劑之組合物。
简体摘要：本发明系有关对Ga1R3受体具有选择拮抗性之酮衍生物。本发明提供一种医药组合物，其包含治疗有效量之本发明化合物及医药可接受性载剂。本发明亦提供一种借由结合治疗有效量之本发明化合物及医药可接受性载剂所制得之医药组合物。本发明另提供一种制造医药组合物之方法，其包括结合治疗有效量之本发明化合物及医药可接受性载剂。本发明亦提供一种治疗患有抑郁及／或焦虑症之个体之方法，其包括对该个体投予有效治疗该个体抑郁及／或焦虑症之量之本发明化合物。本发明亦提供一种于个体中治疗抑郁及／或焦虑症之方法，其包括对该个体投予包含医药可接受性载剂及治疗有效量之Ga1R3受体拮抗剂之组合物。

7. 发明申请

US20040019050A1 Selective NPY (Y5) antagonists (triazines) 审中-公开
标题翻译：选择性NPY（Y5）拮抗剂（三嗪）
公开(公告)号：US20040019050A1
公开(公告)日：2004-01-29
申请号：US10420238
申请日：2003-04-22
申请人： Synaptic Pharmaceutical Corporation
发明人： Mohammad R. Marzabadi , Stewart A. Nobel , Mahesh N. Desai
IPC分类号： A61K031/53 , C07D251/18 , C07D251/48 , C07D43/02
CPC分类号： C07D401/12 , C07D251/70 , C07D277/28 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04
摘要： This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三嗪衍生物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

8. 发明申请

US20030113772A1 DNA encoding human alpha 1 adrenergic receptors and uses thereof 审中-公开
公开(公告)号：US20030113772A1
公开(公告)日：2003-06-19
申请号：US10238667
申请日：2002-09-10
申请人： Synaptic Pharmaceutical Corporation
发明人： Jonathan A. Bard , Richard L. Weinshank , Carlos C. Forray
IPC分类号： C12Q001/68 , C07H021/04 , C12P021/02 , C12N005/06 , C07K014/705
CPC分类号： C12Q1/6876 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/10 , A01K2227/105 , A01K2267/02 , A01K2267/03 , A01K2267/0393 , A61K38/00 , C07K14/70571 , C12N15/85 , C12N15/8509 , C12Q1/6897 , C12Q2600/158 , G01N33/9433 , G01N2500/10
摘要： This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.

9. 发明申请

US20030073167A1 DNA encoding SNORF36 receptors 失效
标题翻译：编码SNORF36受体的DNA
公开(公告)号：US20030073167A1
公开(公告)日：2003-04-17
申请号：US10146835
申请日：2002-05-16
申请人： Synaptic Pharmaceutical Corporation
发明人： Beth E. Borowsky , Kristine L. Ogozalek , Parul P. Lakhlani , Nika Adham
IPC分类号： C07K014/705 , C12P021/02 , C12N005/06 , C07H021/04
CPC分类号： C07K14/705 , A01K2217/05 , A01K2217/075 , A61K38/00 , G01N33/567 , G01N2333/726
摘要： This invention provides isolated nucleic acids encoding mammalian SNORF36 receptors, purified mammalian SNORF36 receptors, vectors comprising nucleic acid encoding mammalian SNORF36 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF36 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF36 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF36 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF36 receptors, methods of isolating mammalian SNORF36 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF36 receptors, as well as methods of determining binding of compounds to mammalian SNORF36 receptors, methods of identifying agonists and antagonists of SNORF36 receptors, and agonists and antagonists so identified.
摘要翻译：本发明提供编码哺乳动物SNORF36受体的分离的核酸，纯化的哺乳动物SNORF36受体，包含编码哺乳动物SNORF36受体的核酸的载体，包含该载体的细胞，针对哺乳动物SNORF36受体的抗体，用于检测编码哺乳动物SNORF36受体的核酸的核酸探针，与编码哺乳动物SNORF36受体的核酸的独特序列互补的反义寡核苷酸，表达编码正常或突变型哺乳动物SNORF36受体的DNA的转基因非人动物，分离哺乳动物SNORF36受体的方法，治疗与哺乳动物活性相关的异常的方法 SNORF36受体以及确定化合物与哺乳动物SNORF36受体结合的方法，识别SNORF36受体的激动剂和拮抗剂的方法，以及如此鉴定的激动剂和拮抗剂。

10. 发明申请

US20030032580A1 Use of agonists or antagonists of the 5-HT7 receptor to treat disorders of the bladder 审中-公开
公开(公告)号：US20030032580A1
公开(公告)日：2003-02-13
申请号：US10228779
申请日：2002-08-26
申请人： Synaptic Pharmaceutical Corporation
发明人： Douglas A. Craig
IPC分类号： A61K031/00
CPC分类号： A61K31/517 , A61K31/00 , A61K31/404 , A61K31/4045 , A61K31/438 , A61K31/439 , A61K31/475 , A61K31/48 , A61K31/495 , A61K31/496
摘要： The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT7 receptor antagonist or an antagonist that binds to both 5-HT7 and 5-HT2B receptors. The invention also provides a method of treating urinary retention in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT7 receptor agonist or an agonist that activates both 5-HT7 and 5-HT2B receptors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式